TickerTalks
Browse all tickers →
TickerTalks›$ANRO
ANANRO

Alto Neuroscience, Inc.

$ANRO·$1.3B·Biotechnology·Healthcare
$35.13-3.2%1Y+822.0%
Mentions · last 7 days
0
Price updated 15m ago
ANANRO
$ANROAlto Neuroscience, Inc.
$35.13-3.22%0 posts
AI analysisFundamentalsVoices on X
Loading…

What it does

Plain-English summary of the business — what they sell and how they make money.

Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $ANRO.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $ANRO

Partial — fee-based midstream revenue has limited direct commodity price exposure but volume ties to upstream production activity.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+51.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-14.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
18.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-5.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-46.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 12, 2026$-0.65$-0.73+11.5%
Q1 2026May 13, 2026$-0.80$-0.56-42.9%
Q4 2025Mar 16, 2026$-0.45$-0.56+19.6%
Q3 2025Nov 12, 2025$-0.52$-0.66+21.2%
Next earningsWed, Nov 11·consensus EPS $-0.67

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$0———$-0.65$-19.8M
Q1 FY26$0———$-0.80$-27.6M
Q4 FY25$0———$-0.51$-11.5M
Q3 FY25$0———$-0.52$-9.9M

Forward consensus

5-year forecast · up to 6 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$0$0 – $0-$2.78-$2.96 – -$2.470
FY27$0$0 – $0-$3.07-$3.91 – -$1.920
FY28$4.7M$4.7M – $4.7M-$3.10-$4.46 – -$2.236
FY29$52.5M$52.5M – $52.5M-$2.67-$2.67 – -$2.674
FY30$213.5M$213.5M – $213.5M-$0.89-$0.89 – -$0.893

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.93%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+22.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+62.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 35.1M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.7% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.095-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 7 other (6 awards · 1 gift) in window

See when $ANRO insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeAug 278-K — Item 5.02: Officer or director change
AI summary

Alto Neuroscience promoted Nicholas C. Smith from CFO and CBO to President and CFO of the company, effective August 26, 2026. CEO Amit Etkin, M.D., Ph.D. relinquishes the President title but continues as Chief Executive Officer and principal executive officer. Administrative leadership restructuring; Smith now serves as both president and principal financial officer.

8-KMaterial agreementJul 148-K — Item 1.01: Material agreement
AI summary

Alto Neuroscience, Inc. (ANRO, Mountain View CA) filed a current report on July 13, 2026 (filed July 14) disclosing entry into a material definitive agreement (Item 1.01) with exhibits. A new material agreement for a precision psychiatry company may signal a licensing deal, research collaboration, pharma partnership, or financing arrangement. The specific agreement terms are in attached exhibits.

424B5Prospectus supplement (offering)Jul 14424B5
AI summary

Alto Neuroscience, Inc. (ANRO, NYSE) filed a 424B5 prospectus supplement on July 14, 2026 for the registered direct offering of 3,776,436 shares of common stock ($0.0001 par value) at a fixed price of $26.48 per share — equal to the last reported sale price on July 10, 2026 — raising approximately $100 million in gross proceeds. ANRO is an emerging growth company and smaller reporting company. This is live equity dilution; proceeds are intended for clinical development and operations. The offering follows the concurrent Item 1.01 material agreement, suggesting the equity raise may relate to a partnership capital call or clinical advancement funding.

3New insider — initial holdingsMay 293
8-KOfficer or director changeMay 288-K — Item 5.02: Officer or director change
8-KOfficer or director changeMay 138-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
S-3Shelf registrationApr 10S-3
8-KMaterial agreementMar 168-K — Item 1.01: Material agreement · Item 3.02: Unregistered equity sale · Item 8.01: Other event
+ 24 other (9 13Gs · 3 earnings 8-Ks · 2 10-Qs · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officerbusinesswire.com·4d agoAWM Investment Company Inc. Purchases New Holdings in Alto Neuroscience, Inc. $ANROdefenseworld.net·5d agoAlto Neuroscience (NYSE:ANRO) Reaches New 1-Year High – Still a Buy?defenseworld.net·6d agoAlto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlightsbusinesswire.com·19d agoAlto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of “Moderate Buy” by Analystsdefenseworld.net·28d ago

In themes

Explore the broader themes this ticker is being talked about under.

AI Precision Medicine

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport